Why Cedar Health Tapped a Finance Veteran to Lead Its Clinical Trial Network

DALLAS, TX – September 24, 2026 – The clinical trial site industry is officially outgrowing the "doctor-as-entrepreneur" era. In a move that signals the rapid commercial maturation of community-based research, Cedar Health Research announced today the appointment of Jody Staggs as its new Chief Executive Officer, effective September 14.

Staggs succeeds Dr. Mimi Fenton, an epidemiologist who guided the Dallas-based network through a crucial two-year foundational period. But Staggs is not a physician or a traditional clinical trialist. He arrives fresh from a tenure as President and CEO of SWK Holdings Corporation, a publicly traded life sciences specialty finance company.

This executive transition is a masterclass in the evolving demands of the clinical research sector. Today, regional site networks require complex capital structuring, sophisticated contract negotiation, and scalable operational models to compete for top-tier pharmaceutical trials.

The Capital Shift in Clinical Site Networks

For decades, the clinical trial landscape was dominated by fragmented, independent testing centers run by local physicians. However, the market has recently seen massive consolidation driven by private equity and institutional capital. Large sponsors and Contract Research Organizations (CROs) increasingly prefer multi-site integrated networks that guarantee high enrollment velocity, unified standard operating procedures, and centralized budgeting.

Staggs brings a corporate finance and transactional background perfectly suited for this new reality. At SWK Holdings, he oversaw bespoke credit, structured debt, and royalty monetization transactions targeting commercial-stage life sciences companies. Crucially, he also led the operational restructuring of SWK’s pharmaceutical manufacturing subsidiary, MOD3 Pharma, giving him direct experience in clinical supply chains and FDA compliance.

"Cedar has built something special: a talented and mission-driven team, strong relationships across the clinical research ecosystem, and a delivery model designed to bring research opportunities to the patients and communities who can benefit most," Staggs said regarding his appointment. "We are poised to expand the number of patients we serve, strengthen our partnerships with sponsors and healthcare providers, and build a scalable organization that delivers exceptional research experiences for patients and clients alike."

Dr. Fenton’s departure after approximately two years reflects a natural operational transition for venture-backed clinical platforms. During her tenure, she spearheaded the integration between Cedar and Aspen Insights, deploying an artificial intelligence engine that matches electronic medical records to trial protocols. She also brokered the organization's flagship partnership with Texas Native Health. With the clinical methodology and compliance rigor firmly established, Cedar’s board is now pivoting toward commercial scaling and geographic network rollouts.

"We are grateful to Mimi for her leadership," Staggs added. "During her tenure, Cedar expanded its capabilities and partnerships and advanced its mission of increasing access to clinical research. We remain committed to that mission and wish her well."

Solving the Biopharma Diversity Mandate

The strategic timing of this leadership change cannot be overstated, particularly given the regulatory tsunami currently hitting the biopharmaceutical industry. Under the Food and Drug Omnibus Reform Act of 2022 (FDORA), Congress mandated that sponsors submit Diversity Action Plans (DAPs) for Phase 3 and other pivotal clinical studies.

The FDA has made it clear that diversity is no longer a "nice-to-have" public relations talking point; it is a strict regulatory requirement. Sponsors must delineate specific enrollment targets broken down by race, ethnicity, sex, and age group based on disease epidemiology. Failure to meet these benchmarks risks delayed advisory committee reviews or severe label limitations.

As one regulatory consultant observing the space noted, "Global pharma development pipelines continue to fail at community-level diverse trial recruitment because they rely on broad digital marketing rather than local trust."

This is where Cedar Health Research’s business model directly solves an acute pressure point. Unlike massive academic medical centers that draw homogeneous cohorts living near tertiary medical campuses, Cedar deploys a decentralized, community-embedded model. The network operates five active locations across the Dallas-Fort Worth metroplex: Dallas, Euless, Fort Worth, Burleson, and a highly specialized embedded site within Texas Native Health.

The Texas Native Health Blueprint

The collaboration with Texas Native Health (TNH) serves as Cedar's flagship proof-of-concept and a primary reason why leading biopharmaceutical companies like Amgen, Sanofi, and Eli Lilly are paying close attention.

American Indian and Alaska Native populations suffer from a 36% higher rate of diabetes than non-Hispanic white populations, and approximately half of Native American adults suffer from obesity. Despite this disproportionate disease burden, Native Americans historically make up less than 0.5% of participants in FDA registration trials.

Cedar addressed this by embedding its clinical trial infrastructure directly inside TNH, a facility that already provides free comprehensive primary care, behavioral health, and pharmacy services to Indigenous populations. By placing coordinators inside the primary care clinic where patients already maintain deep trust with their providers, Cedar bypasses the skepticism that typically dooms diverse recruitment efforts.

The results speak for themselves. In a recent cardiometabolic and obesity trial partnership with Amgen’s RISE (Representation in Clinical Research) initiative, Cedar met 100% of its enrollment target for underrepresented populations. Astonishingly, Native Americans accounted for half of the site's total enrolled cohort, and study retention held at approximately 90%—bucking the industry trend of high drop-out rates for historically underserved groups.

Furthermore, Cedar does not rely on direct-to-consumer print or social media ads to find these patients. It operates on real-time data pipelines. Through its affiliation with Aspen Insights, the network uses an AI-driven natural language processing tool called Aspen Forge. Because more than 90% of clinical trial inclusion criteria are buried in unstructured physician notes, this AI extracts clinical phenotyping data to identify trial candidates long before they present for an acute visit.

Dallas-Fort Worth as a Clinical Hub

Staggs assumes control of an organization perfectly positioned within an emerging national hotspot for life sciences. Boosted by the Advanced Research Projects Agency for Health (ARPA-H) customer experience hub at Dallas’ Pegasus Park, the Dallas-Fort Worth metroplex is rapidly becoming a premier proving ground for decentralized clinical trials.

The region's unique demographic mix reflects broader national shifts, making it an ideal testbed for sponsors desperate to meet their FDA diversity quotas. By partnering with local primary care networks and leveraging advanced AI platforms, specialized site networks like Cedar are attracting clinical trial R&D spending directly into North Texas healthcare infrastructure—spending that was historically reserved for traditional hubs like Boston, San Francisco, or Raleigh-Durham.

"I look forward to listening to and learning from the Cedar team, our patients, and our partners as we write this next chapter," Staggs noted in his statement.

That next chapter will likely involve institutional capital expansion, syndicated credit facilities for site rollups, or eventual strategic consolidation. With a finance veteran at the helm and a proven, scalable model for diverse patient recruitment, Cedar Health Research has officially signaled its intent to transition from a regional player into a dominant commercial platform in the global clinical research ecosystem.